A broad-spectrum flu vaccine is being developed to give better immunity to seasonal influenza strains and increased protection against future influenza pandemics.

The technology was created by researchers at the Australian National University and the University of Adelaide, who set up Gamma Vaccines to commercialise their ideas.

In 2013, Gamma Vaccines signed a three-way development agreement with Bio Farma and SOHO Industri Pharmasi to develop, manufacture, trial, and distribute the vaccine in Indonesia and other Association of Southeast Asian Nations (ASEAN) countries.